Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.
After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.
One of medicine’s costliest treatment areas could become even more pricey as Biogen seeks to layer the company’s $750,000 spinal muscular atrophy drug on top of the $2.1 million-per-patient Novartis gene therapy Zolgensma.
The U.S. National Institutes of Health (NIH) said data from the company’s trial of Gilead Sciences Inc.’s remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.
As the mortality figures for COVID-19 continued to rise, people are wondering where they will stop. The actual death toll for COVID-19 will not be calculable for some time, but there are early indications that the mortality rate may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration announced data from tests of the company’s gene therapy Zolgensma had been manipulated.
The U.S. spends about twice what other high-income nations do on health care but has the lowest life expectancy and the highest infant mortality rates, a new study suggests.
Even though infant and child mortality rates in wealthy nations have been steadily declining for decades, American children are still more likely to die than kids in other affluent countries, a U.S. study suggests.
Being overweight or obese is linked to a higher risk of dying prematurely than being normal weight and the risk rises sharply as the extra pounds pile on, scientists said.